title: Deal watch: Phase III antibody targeting tumour pH acquired in Prometheus deal.
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000276:immunology* / Q000378:metabolism; D000071231:Carbonic Anhydrase IX; D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use*; D002256:Carbonic Anhydrases / Q000276:immunology* / Q000378:metabolism; D002292:Carcinoma, Renal Cell / Q000378:metabolism / Q000628:therapy; D017326:Clinical Trials, Phase III as Topic; D017277:Drug Approval; D004345:Drug Industry; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007680:Kidney Neoplasms / Q000378:metabolism / Q000628:therapy; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000378:metabolism / Q000628:therapy*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D002257:Carbonic Anhydrase Inhibitors; D011993:Recombinant Fusion Proteins; C089226:CA9 protein, human; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases